Self-Assessment Post-Test

SELF-ASSESSMENT POST-TEST There are no fees for participating and receiving CME credit for this activity. During the period of September 2003 through September 30, 2004, participants must: 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine. New Perspectives on Benign Prostatic Hyperplasia 1. Lower urinary tract symptoms (LUTS) include: a. Hyperreactivity to alpha stimuli b. Hypertonic bladder neck c. Hypertonic prostatic smooth muscle d. All of the above 2. Patients with LUTS rated which of the following as the most bothersome urinary symptom? a. Nocturia b. Urgency c. Hesitancy d. Bladder pain 3. Baseline prostate volume is not related to which of the following? a. Progression of benign prostatic hyperplasia (BPH) b. Negative outcomes related to BPH, such as acute urinary retention and need for surgery c. Response to drug therapy d. None of the above 4. Which of the following has not been demonstrated to be an effect of the 5-α-reductase inhibitors (finasteride, dutasteride)? a. Decreased prostate volume b. Increased symptom score c. Increased urinary peak flow rate d. Small increase in erectile dysfunction 5. Findings of a randomized, placebo-controlled multicenter study of terazosin in the treatment of BPH indicated that treatment effects of terazosin, 10 mg, include: a. Decreased symptom score b. Increased peak urinary flow rate c. Small increase in weight loss, dizziness, and weakness d. All of the above 6. The VA Cooperative Study compared 2 classes of drugs: an α 1-blocker (terazosin) and a 5-α-reductase inhibitor (finasteride). Findings of this study indicate that outcomes (AUA symptom score, peak urinary flow rate, prostate volume) were most favorable for the patients who received: a. Finasteride b. Terazosin c. A combination of finasteride and terazosin 7. According to the results of the Medical Therapy of Prostatic Symptoms trial (doxazosin, finasteride, or a combination of the 2 drugs), which of the following statements is not true? a. The combination is the most effective strategy for delaying or preventing clinical progression of BPH b. Finasteride has a potent positive effect on LUTS c. Both finasteride and doxazosin significantly decrease progression of LUTS d. Finasteride prevents the progressive growth of BPH 8. Acute urinary retention early in the course of BPH voiding dysfunction may be precipitated by which of the following? a. Decongestants containing α-agonists b. Diuretic or alcohol ingestion c. A forced and prolonged delay in voiding d. All of the above e. None of the above 9. In the PLESS study, prostate-specific antigen (PSA) values of patients taking finasteride tended to be _______ than in the other groups. a. Lower b. Higher 10. Among men with symptoms of BPH, the rate of acute urinary retention requiring surgical relief is: a. Less than 1% per year b. 1% to 2% per year c. 3% to 5% per year d. Greater than 6% per year EVALUATION FORM New Perspectives on Benign Prostatic Hyperplasia Project ID: 031620 ES 13 Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. Please note, a statement of participation is issued only upon receipt of your completed evaluation form. Please Print Clearly Name: Street Address: City: Phone Number: E-mail: State: Specialty: Box/Suite: Zip Code: Fax Number: VOL. 5 SUPPL. 4 2003 REVIEWS IN UROLOGY S51 Answer key: 1. d, 2. a, 3. d, 4. b, 5. d, 6. c, 7. b, 8. d, 9. a, 10. b Please answer the following questions by circling the appropriate rating: (5 = Outstanding; 4 = Good; 3 = Satisfactory; 2 = Fair; 1 = Poor) EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES Upon completion of this activity, participants should be able to: • Discuss how 5-α-reductase inhibitors and α-blockers can be used in combination to optimally treat BPH • Review the role of the primary care physician in the treatment of patients with BPH • Explain how 5-α-reductase inhibitors prevent the progression of BPH • Discuss how to evaluate lower urinary tract symptoms and BPH • Explain PSA changes associated with 5-α-reductase inhibitors 5 5 5 5 5 4 4 4 4 4 3 3 3 3 3 2 2 2 2 2 1 1 1 1 1 5 5 5 5 5 5 5 5 4 4 4 4 4 4 4 4 3 3 3 3 3 3 3 3 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 OVERALL EFFECTIVENESS OF THE ACTIVITY • • • • • • • • Objectives were related to overall purpose/goal(s) of activity Related to my practice needs Will influence how I practice Will help me improve patient care Stimulated my intellectual curiosity Overall quality of material Overall, the activity met my expectations Avoided commercial bias or influence Will the information presented cause you to make any changes in your practice? If yes, please describe any change(s) you plan to make in your practice as a result of this activity: How committed are you to making these changes? Yes___ No___ 5 4 (Very) 3 2 1 (Not at all) Additional comments about this activity: Do you feel future activities on this subject matter are necessary and/or important to your practice? Please list any other topics that would be of interest to you for future educational activities: Degree: ❒ MD ❒ DO ❒ PharmD ❒ RN Yes___ No___ ❒ PA ❒ BS ❒ Other: To obtain a statement of participation, you must complete the post-test by selecting the best answer to each question, complete the evaluation form, and mail or fax your completed evaluation form to the Postgraduate Institute for Medicine. POST-TEST ANSWER KEY 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ If you wish to receive credit for this activity, please fill in your name and address and mail/fax to: ❒ I completed the entire activity and claim 2.0 credit hours. Postgraduate Institute for Medicine P.O. Box 260620 Littleton, CO 80163-0620 Fax: (303) 790-4876 ❒ I completed only part of the activity and claim credit hours based on ____ hours of participation. Signature: Release date: September 2003 Expiration: Credit will be awarded for required materials postmarked or received no later than September 30, 2004. Certificates will be mailed within 1 month of receipt of these materials. S52 VOL. 5 SUPPL. 4 2003 REVIEWS IN UROLOGY